<DOC>
	<DOCNO>NCT01824602</DOCNO>
	<brief_summary>The primary study objective evaluate dose-dependent efficacy eslicarbazepine acetate administer dos 600 , 1200 , 1800 mg 3-week period , compare placebo , therapy patient acute mania . The secondary objective study ) evaluate safety tolerability eslicarbazepine acetate ( BIA 2-093 ) administer dose 600 , 1200 , 1800 mg compare placebo , b ) ass duration onset action different dose group , c ) monitor appearance depressive symptom .</brief_summary>
	<brief_title>Efficacy Safety Eslicarbazepine Acetate ( BIA 2-093 ) Acute Manic Episodes Associated With Bipolar I Disorder</brief_title>
	<detailed_description>This phase II , double-blind , fix multiple dose , randomise , placebo-controlled , multicentre clinical trial patient diagnosis bipolar I disorder experienced acute manic ( include mix ) episode . Patients meet selection criterion randomisation visit ( V ) ( V2 , Day 1 ) randomise 1 4 treatment group : 600 , 1200 , 1800 mg eslicarbazepine acetate , placebo . Patients start assigned treatment Day 1 follow 3 week . On Day 10 , patient show improvement switch open-label escape therapy establish antimanic therapy . Patients could hospitalize screening time study investigator 's discretion . Following randomisation ( V2 , Day 1 ) , patient assess Days 3 , 7 , 10 , 14 , 21 , 28 , 56 , could either enter recurrence prevention study , study drug could taper could undergo follow-up assessment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Aged 18 year . A documented diagnosis bipolar I disorder accord Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSMIV ) criterion ( i.e. , 296.0 , 296.4 296.6 ) . Currently display acute manic ( include mix ) episode accord DSMIV criterion . A Young Mania Rating Scale ( YMRS ) total score 20 great . Symptoms current manic episode start within 2 week prior Randomization ( V2 , Day 1 ) . Able undergo standard evaluation , include clinical interview , rating laboratory study . Signed informed consent form ( ICF ) . Postmenopausal otherwise incapable become pregnant reason surgery tubal ligation . In case woman childbearing potential , patient present serum pregnancy test consistent nongravid state use doublebarrier contraception least poststudy visit ( PSV ) . History schizophrenia schizoaffective disorder , psychotic feature rapid cycling . Currently treat carbamazepine oxcarbazepine . History unresponsiveness , intolerance hypersensitivity relate compound ( carbamazepine , oxcarbazepine licarbazepine ) . Use depotneuroleptics current manic episode Abuse stimulating drug use systemic sympathicomimetic drug within previous 2 week . Electroconvulsive therapy ( ECT ) within previous 3 month History dependence chronic abuse alcohol , drug medication within last year . Judged clinically risk harm self others . Second thirddegree atrioventricular blockade correct pacemaker . Relevant ECG laboratory abnormality . Calculated creatinine clearance &lt; 30 ml/min [ men : ( 140age ) x weight / serum creatinine x 72 ; woman : ( 0.85 ) ( 140age ) x weight / serum creatinine x 72 . Age year , weight kg , serum creatinine mg/dl ] . Pregnancy nursing . Participation drug clinical trial within last 2 month Randomization visit Not ensure capability perform trial comply study protocol ( e.g . mental retardation severe inability communicate ) ; Any uncontrolled clinically relevant disorder . Previous treatment Eslicarbazepine Acetate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>BIPOLAR I DISORDER , Eslicarbazepine acetate</keyword>
</DOC>